Business Model Breakdown
How Twist Bioscience Corp Makes Money
TWST
Market Cap
$4.2B
Annual Revenue
$439M
Profit Margin
-19.9%
Employees
979
The Short Version
Twist Bioscience specializes in creating and selling custom synthetic DNA products and services, primarily leveraging a unique, high-throughput silicon-based platform. This platform allows them to synthesize DNA more efficiently, quickly, and affordably than traditional methods, catering to diverse customers in drug discovery, diagnostics, agriculture, and academic research. They are also investing heavily in pioneering DNA as a long-term data storage medium, developing a potentially revolutionary new market.
Where the Revenue Comes From
Gene Synthesis Products (primary revenue driver)
Oligonucleotide Pools
Antibody Discovery and Engineering Libraries
DNA Data Storage Research Services (early stage)
Who buys: Biotechnology and pharmaceutical companies, academic and government research institutions, industrial and agricultural companies, and large technology/data enterprises.
Why It Works (Competitive Advantages)
- ✔Proprietary silicon-based DNA synthesis platform for high throughput and precision
- ✔Scalability and cost-effectiveness at large volumes
- ✔Strong intellectual property portfolio protecting core technology
- ✔First-mover advantage and pioneering efforts in DNA data storage
Economic Moat: Narrow (Intangible Assets/IP (patents on silicon-based DNA synthesis and applications), Switching Costs (customers integrating Twist's platform into their R&D workflows), Cost Advantages (achieved through scale and efficiency of its platform))
What Our Analysis Says
DVR Score as of June 2, 2026
Twist Bioscience maintains its high-risk, high-reward profile with compelling 10x growth potential, driven by its unique silicon-based DNA synthesis platform and strategic entry into DNA data storage. Q2 FY26 results confirmed strong revenue growth and expanded clonal gene offerings, reinforcing its market opportunity and technological moat. However, the reported EPS miss for Q2 FY26 and ongoing insider selling, including by the CEO, reiterate the near-term financial execution challenges and concerns about cash flow generation previously highlighted. While the long-term vision is strong, consistent operational profitability remains elusive, contributing to a balanced score that reflects both substantial upside and persistent risks.